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Abstract
Background: Dicer, Ago2 and TRBP are the minimum components of the human RNA-induced
silencing complex (RISC). While Dicer and Ago2 are RNases, TRBP is the double-stranded RNA
binding protein (dsRBP) that loads small interfering RNA into the RISC. TRBP binds directly to
Dicer through its C-terminal domain.
Results: We show that the TRBP binding site in Dicer is a 165 amino acid (aa) region located
between the ATPase and the helicase domains. The binding site in TRBP is a 69 aa domain, called
C4, located at the C-terminal end of TRBP. The TRBP1 and TRBP2 isoforms, but not TRBPs lacking
the C4 site (TRBPsΔC4), co-immunoprecipitated with Dicer. The C4 domain is therefore
necessary to bind Dicer, irrespective of the presence of RNA. Immunofluorescence shows that
while full-length TRBPs colocalize with Dicer, TRBPsΔC4 do not. tarbp2-/- cells, which do not
express TRBP, do not support RNA interference (RNAi) mediated by short hairpin or micro RNAs
against EGFP. Both TRBPs, but not TRBPsΔC4, were able to rescue RNAi function. In human cells
with low RNAi activity, addition of TRBP1 or 2, but not TRBPsΔC4, rescued RNAi function.
Conclusion: The mapping of the interaction sites between TRBP and Dicer show unique domains
that are required for their binding. Since TRBPsΔC4 do not interact or colocalize with Dicer, we
suggest that TRBP and Dicer, both dsRBPs, do not interact through bound dsRNA. TRBPs, but not
TRBPsΔC4, rescue RNAi activity in RNAi-compromised cells, indicating that the binding of Dicer
to TRBP is critical for RNAi function.
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Background
RNA interference (RNAi) is a natural mechanism used by
eukaryotes for gene silencing. This mechanism uses small
double-stranded (ds)RNA, named micro (mi) or small
interfering (si) RNAs, which are complementary to a tar-
get gene to degrade the corresponding mRNA or block its
translation. The dsRNA triggers the assembly of a ribonu-
cleoprotein complex called the RNA-induced silencing
complex (RISC) [1]. The mechanism and complex com-
position has been best studied in Drosophila melanogaster.
This is an enzymatic process that involves RNAse III-like
proteins (Dicer and Drosha) and a dsRNA binding protein
(dsRBP; R2D2 and Loquacious) [2-4]. The second step,
which leads to the cleavage of the target mRNA, includes
an Argonaute (Ago) protein [5,6].
Mammalian cells have a single Dicer protein, with a
molecular weight of ~200 kDa. Dicer contains an ATPase/
RNA helicase domain, a DUF domain, a PAZ domain, two
RNase III domains and a dsRNA binding domain
(dsRBD) [5]. The Dicer PAZ domain associates with the
PIWI domain of Ago2 [7]. Dicer is responsible for cleaving
the dsRNA trigger (miRNA or siRNA) so it can be loaded
into the RISC. Ago2 is then recruited to the RISC where it
cleaves the target mRNA or mediates translation inhibi-
tion after its association with the complementary strand
from the mi/siRNA [8]. Dicer knock-out (Dcr-/-) mice and
cells are not viable indicating a major function for this
protein during development and normal cell function [9].
In human cells, the dsRBP that associates with Dicer is the
TAR RNA binding protein, TRBP. This protein is required
for RNAi function mediated by both siRNAs and miRNAs
[10-12], where it acts as a biosensor in the choice of
dsRNA loaded into the RISC [13,14]. Furthermore, Dicer,
TRBP and Ago2 are necessary and sufficient for in vitro
reconstitution of RNAi activity [15].
TRBP1 and TRBP2 are isoforms of the cellular protein
TRBP which was isolated by its ability to bind the human
immunodeficiency (HIV)-1 TAR RNA and characterized
for its stimulation of the expression of the HIV long termi-
nal repeat in human and murine cells [16-20]. TRBPs have
two dsRBDs, a KR-helix motif within dsRBD2 and a Medi-
pal domain that mediates protein-protein interactions
[21-25]. TRBPs also bind to PKR and PACT through their
dsRBDs and to Merlin, Dicer and PACT through their
Medipal domain [11,17,25-27]. TRBPs are encoded by the
tarbp2 gene. Two adjacent promoters initiate transcription
of alternative first exons for TRBP1 and TRBP2 mRNAs
and as a consequence, in comparison to TRBP1, TRBP2
has 21 additional amino acids (aa) [28,29]. TRBPs have
functional activities in spermatogenesis, cell growth,
oncogenesis and viral replication linked to their RNA- and
protein-binding abilities [27,30-32]. Among these, the
TRBP-Dicer interaction and its function as part of the RISC
has been identified as an important component of the
RNAi pathway. In this paper, we further characterize the
specific domains in TRBP and Dicer that are required for
their interaction and we analyze the consequences of this
interaction in RNAi function.
Results
TRBP Medipal domain interacts with Dicer through a 
unique domain in Dicer located between the ATPase and 
the helicase motifs
The TRBP-Dicer interaction was found by immunoprecip-
itation (IP) with a Dicer antibody followed by mass spec-
trometry analysis of the interacting proteins [10,11]. We
independently identified Dicer in a two-hybrid screen
using TRBP as bait. This screen resulted in the identifica-
tion of six clones that interacted with TRBP. Among these,
the only clones which corresponded to an RBP mapped to
Dicer aa 173–431 or aa 267–541 (Fig. 1A). Because both
TRBP and Dicer are dsRBPs, and these corresponding
domains often dimerize [17,25], we also verified if the
Dicer dsRBD (aa 1850–1922) could interact with TRBP,
but no interaction was found. We next expressed the com-
mon sequence between the isolated two-hybrid clones, aa
267–431 called D1, on pGBT9 and showed its interaction
with TRBP2 or TRBP C (Medipal domain) expressed in
pGADGH. This domain was further divided in two halves
expressing aa 267–350 and 350–431. Neither domain
interacted with TRBP, indicating that the 165 aa D1
domain is the smallest TRBP-interacting domain defined
in this assay.
The Medipal domain was previously defined as a protein-
protein interacting domain in TRBP (aa 228–366 or
TRBP-C) that binds Merlin, Dicer and PACT [25]. TRBP
interaction with PACT in this domain has been mapped to
aa 287–366 in TRBP2. To determine if TRBP-Dicer inter-
action can be limited to a shorter domain, we first
expressed the subdomains as C1 and C2 expressing aa
228–339 and 340–366 respectively (Fig. 1B). C1 did not
show an interaction and the expression of C2 repeatedly
induced yeast growth arrest indicating a cytotoxicity of
this domain. The domain was next divided into C3 and
C4 expressing aa 228–297 and 298–366 respectively.
Only C4 showed a specific interaction with D1, indicating
that this subdomain of the Medipal is the active compo-
nent for Dicer binding.
The cellular distribution of Dicer and TRBP has not yet
been fully elucidated. We next examined their localization
in the cell using immunofluorescence with antibodies
directed against endogenous TRBP and Dicer. Interest-
ingly, TRBP localized mainly to the cytoplasm, while
Dicer was distributed throughout the cytoplasm and the
nucleus. We found significant colocalization between
Dicer and TRBP in HeLa cells predominantly in the peri-BMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
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Determination of Dicer-TRBP interaction domains and colocalization Figure 1
Determination of Dicer-TRBP interaction domains and colocalization. A) Dicer interacting domain is located 
in a unique region between the ATPase and the helicase domains. (Top) Schematic representation of Dicer protein 
and its domains. (Bottom) Dicer 173–431 or 267–541 represent the isolated interacting Dicer clones in a two-hybrid screen 
using TRBP as bait. Yeast two hybrid assay using Dicer or Dicer domains expressed in pGADGH vector and their interactions 
with TRBP2 clones expressed in pGBT9 vector. B) The Medipal subdomain in TRBP is located between aa 298 and 
366. (Top) Schematic representation of TRBP2 protein and its domains. (Bottom) Yeast two hybrid assay using TRBP2 or 
TRBP domains expressed in pGADGH vector and their interactions with Dicer domains identified in A and expressed in 
pGBT9 vector. NG means no growth. Shown are representative assays of three independent experiments. Dicer and TRBP2 
schematic representation of full-length proteins are at scale. C) Endogenous TRBP and Dicer colocalize. HeLa cells were 
fixed and labeled with rabbit anti-TRBP673 and mouse anti-Dicer (mAb42) followed by anti-rabbit Alexa Fluor 488 and anti-
mouse Alexa Fluor 546. The cells were mounted and assayed for fluorescence by laser scanning confocal microscopy on a 
Zeiss LSM Pascal 5 microscope. Alexa Fluor 488 and Alexa Fluor 546 fluorescences are represented as green and red, respec-
tively, while merged colors appear as yellow. Images showing the colocalization of the two proteins detected by the yellow 
dots are amplified on the right.BMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
Page 4 of 13
(page number not for citation purposes)
nuclear space (Fig. 1C). These data and previous results
confirm that TRBP and Dicer can interact in a physiologi-
cal environment.
The C4 sequence within the Medipal domain of TRBP is 
necessary and sufficient to bind Dicer in mammalian cells
To determine the role of the C4 domain in the protein
context, we used a complete TRBP knock-down environ-
ment. Using murine tail embryonic fibroblasts (TEFs)
tarbp2 knock-out cells [26,32], we evaluated the impor-
tance of the C4 domain in TRBP on the interaction
between TRBP and Dicer. We expressed TRBP1 and TRBP2
as Myc-tagged proteins as previously [25], and Myc-
TRBP1ΔC4 and Myc-TRBP2ΔC4 lacking this domain.
TRBPsΔC4 were tested for their binding to Dicer by IP
(Fig. 2). In conditions where Myc-TRBP1 interacts with
endogenous Dicer, Myc-TRBP1ΔC4 did not interact with
Dicer, whether the IP was performed with an anti-Myc or
an anti-Dicer antibody (Fig. 2A). Results with Myc-TRBP2
and Myc-TRBP2ΔC4 were similar (Fig. 2B). We have pre-
viously excluded a binding of TRBP-Dicer through the
dsRBDs in TRBP or through RNA [11]. The loss of TRBP-
Dicer interaction in the absence of the C4 domain, but in
the presence of RNA, further argues against the involve-
ment of RNA in the interaction. These combined results
(Figs. 1 and 2) indicate that the C4 domain is necessary
and sufficient to mediate the interaction with Dicer and
that no other cellular protein or RNA can rescue the lack
of interaction between the mutant TRBP and Dicer in
mammalian cells.
TRBP, but not TRBPΔC4 colocalizes with Dicer in cells
To set up conditions to compare the cellular distribution
of wild-type and truncated TRBPs, we first expressed
TRBP1 and TRBP2 Myc-tagged proteins in HeLa cells. The
cellular distribution of the Myc-tagged proteins, as well as
their colocalization with Dicer was consistent with the
endogenous localization of TRBP (Fig. 3A compared with
1C). Importantly, we found the tagged TRBP constructs
co-localized with Dicer in the perinuclear space.
To further define the importance of the C4 subdomain
within TRBP Medipal, we expressed Myc-TRBP1ΔC4 and
Myc-TRBP2ΔC4 in the same conditions as the wild type
proteins (Fig. 3B). With these mutants, we observed a
marked change in cellular distribution as compared to the
wild-type proteins. Of importance, the mutant proteins
did not colocalize with Dicer in the perinuclear space and
for TRBP2ΔC4, a clear relocalization to the plasma mem-
brane was observed. These results emphasize the impor-
tance of the C4 subdomain within the Medipal domain as
a major determinant in the cellular distribution of TRBP.
To further verify the distributions of full-length TRBP2 as
compared to TRBP2ΔC4, their localization was examined
in relation to an EGFP-tagged TRBP2 construct. EGFP-
TRBP2 and Myc-TRBP2 or Myc-TRBP2ΔC4 were coex-
pressed as previously in HeLa cells. The colocalization of
the EGFP-tagged form of TRBP2 with the Myc-tagged form
of TRBP2 is shown by an extensive yellow coloration in
the cytoplasm (Fig. 3C). In comparison, colocalization of
Myc-TRBP2ΔC4 with EGFP-TRBP2 was significantly
reduced, mainly due to a shift of the truncated protein to
the cellular membrane. This further supports the observa-
tion that the cellular distribution of truncated TRBP2 sig-
nificantly differs from that of the full-length protein.
TRBP is required for RNA interference mediated by shRNA 
or exogenous miRNA against EGFP in murine cells
The requirement for TRBP in the RNAi pathway has been
shown using cells that have been partially knocked down
for TRBP using siRNAs [10,11]. To determine RNAi activ-
ity in a complete TRBP knock-down environment, we
used tarbp2-/- cells previously described [26] compared to
tarbp2+/- and wild type murine embryo fibroblasts (MEF).
To have a qualitative and a quantitative assay, we
designed shRNAs against EGFP, and exogenous miRNAs
that have the siRNA sequence against EGFP in an miR30
backbone, as previously shown for another target [33]
(Fig. 4A). Although these constructs were both active in
MEF and tarbp2+/- cells as shown by EGFP fluorescence, no
significant activity could be detected in tarbp2-/- cells (Fig.
4B). When quantified by flow cytometry, the activity of
sh-EGFP and mi-EGFP was 62 and 60% in MEF, 32 and
28% in tarbp2+/- cells but only 18 and 14% in tarbp2-/- cells
(Fig. 4C). To quantify RNAi activity by another method, a
Western blot analysis was performed and showed no inhi-
bition of EGFP expression by either sh- or miRNAs in
tarbp2-/- cells (Fig. 4D).
TRBP1 and TRBP2, but not TRBPsΔC4 can rescue the 
RNAi pathway in tarbp2-/- cells
To further determine if TRBP could rescue RNAi in tarbp2-
/- murine cells, pcDNA3 or pcDNA3 constructs expressing
TRBP1 or TRBP2 were cotransfected with EGFP and
shRNA against EGFP and verified for cell fluorescence and
protein expression by Western blot (Fig. 5). Consistent
with results in Fig. 4D, pcDNA3 empty vector did not
restore the activity of the shRNA in tarbp2-/- cells. In con-
trast, we observed that RNAi activity was recovered when
TRBP1 or, to a lesser extent, TRBP2, were expressed in the
cells (Fig. 5A). We next transfected the same cells with
Myc-TRBP1, Myc-TRBP2 and their ΔC4 counterparts (Fig.
5B). The full-length TRBP proteins rescued the RNAi func-
tion but the ΔC4 mutants did not, indicating that binding
of the C4 domain in TRBP to the D1 domain in Dicer is
essential for efficient RNAi activity.
TRBP is required for RNAi mediated by shRNA or 
exogenous miRNA against EGFP in human cells
Thus far, all human cell lines described express TRBP, but
we have shown previously that U251MG, an astrocytomaBMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
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cell line, expresses an undetectable amount of TRBP1 and
a decreased amount of TRBP2 compared to HeLa or Jurkat
cells [28,29] (Fig. 6A). To get more insight into the impor-
tance of TRBP in human cell lines, we used the previous
assays to evaluate RNAi function in the relative absence of
TRBP. By fluorescence analysis, we observed no decrease
of EGFP expression with the sh-EGFP constructs and a
weaker decrease of EGFP with the mi-EGFP constructs in
the U251MG cells compared to HeLa cells (Fig. 6B).
Quantification of this knock-down supported our initial
observations. To quantify these observations differently,
we performed flow cytometry analysis and found similar
differences with 57 and 45% decrease in HeLa, but only 6
and 32% decrease in U251MG for sh- and mi-EGFP,
respectively (Fig. 6C). Similarly, Western blots indicated
that U251MG cells poorly support RNAi activity mediated
by shRNAs and mildly support RNAi mediated by miR-
NAs compared to HeLa cells (Fig. 6D).
TRBP1 and TRBP2, but not TRBPsΔC4, can rescue the 
RNAi pathway in human U251MG cells
To further confirm the role of TRBP in RNAi activity in
human cells, U251MG cells were complemented with
either pcDNA3, pcDNA3-TRBP1 or pcDNA3-TRBP2 con-
structs. Their ability to perform RNAi was assessed as pre-
viously. As in murine tarbp2-/- cells, TRBPs were able to
effectively restore RNAi activity in these cells (Fig. 7A),
with TRBP1 being more efficient than TRBP2. pCMV-Myc-
TRBP1 and pCMV-Myc-TRBP2 constructs were equally
effective in restoring RNAi activity, however ΔC4 mutants
were unable to do so despite a similar expression (Fig. 7B,
C). These results confirm that the Dicer-binding domain
of TRBP is required for efficient RNAi activity in human
cells.
Discussion
The minimal active human RISC is composed of three
proteins, Dicer, TRBP and Ago2 [5,15]. Within this com-
plex, Dicer and Ago2 have RNase activities, whereas TRBP
is important in loading the appropriate dsRNA into the
complex [13,14]. Other proteins have been shown to
associate with the RISC, however their roles remain to be
fully determined [34]. We further defined the requirement
for TRBP in RNAi using murine cells that are completely
deficient for TRBP (tarbp2-/-). Using an shRNA and an
miRNA targeting EGFP, these cells displayed low or no
RNAi activity as compared to murine cells expressing
TRBP (tarbp2+/- and MEF) (Fig. 4), confirming that TRBP is
an essential protein for RNAi activity in these cells. The
different approaches used to assess RNAi activity yielded
slightly different intensities of EGFP knock-down, which
can be attributed to the different sensitivities of each tech-
nique. Because no human cell has been shown to have a
complete TRBP deficit, we evaluated the RNAi function in
astrocytes, which have a weak expression of TRBP. This
correlated with a low and moderate activity for the sh- and
miRNAs, respectively, compared to HeLa cells (Fig. 6). In
this case, the difference in RNAi activity between
U251MG and HeLa cells follows the same trend in fluo-
rescence, FACS and western blotting. The ability of
U251MG cells to knock-down GFP expression using
miRNA-based silencing is likely explained by the residual
TRBP2 expression in this cell type. Our results demon-
strate that in both murine and human cells, TRBP is
required for efficient RNAi activity.
The interaction between Dicer and TRBP has been shown
to be direct in vitro and in vivo with no requirement for
The C4 domain is necessary and sufficient to mediate TRBP- Dicer interaction Figure 2
The C4 domain is necessary and sufficient to mediate 
TRBP-Dicer interaction. A) TRBP1 or TRBP1ΔC4-
Dicer interactions by immunoprecipitation. tarbp2-/- 
cells were transfected with none (lanes 1, 4, 7) or 15 μg of 
pCMV-Myc-TRBP1 (lanes 2, 5, 8), pCMV-Myc-TRBP1ΔC4 
(lanes 3, 6, 9). IP was performed with 1 mg of protein and 
anti-Myc antibody (lanes 4–6) or anti-Dicer antibody (lanes 
7–9). 100 μg of proteins from each lysate (input; lanes 1–3) 
and the immunoprecipitated complexes (lanes 4–9) were run 
on a 7.5% SDS-PAGE and blotted using anti-Dicer, anti-TRBP 
672, anti-Myc and anti-actin antibodies. The lower bands in 
lanes 1 and 2 correspond to the migration front. B) TRBP2 
or TRBP2ΔC4-Dicer interactions by immunoprecipi-
tation. tarbp2-/- cells were transfected with none (lanes 1, 4, 
7) or 15 μg of pCMV-Myc-TRBP2 (lanes 2, 5, 8), pCMV-Myc-
TRBP2ΔC4 (lanes 3, 6, 9). IP was performed with 1 mg of 
protein and anti-Myc antibody (lanes 4–6) or anti-Dicer anti-
body (lanes 7–9). 100 μg of proteins from each lysate (input; 
lanes 1–3) and the immunoprecipitated complexes (lanes 4–
9) were run on a 7.5% SDS-PAGE and blotted using anti-
Dicer, anti-Myc and anti-actin antibodies.BMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
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ssRNA, dsRNA or another protein [11]. Although the site
of interaction in TRBP was determined to be in the C-ter-
minal end, no distinct functional domain had been
defined for Dicer [11]. Two-hybrid assays further defined
these domains as aa 267–431 (called D1) in Dicer and aa
298–366 in TRBP2 (called C4) (Fig. 1). D1 is located
between the ATPase and the helicase domains in Dicer. It
was shown previously that ATP is not required for Dicer
function in RNAi [35,36], suggesting that either this
domain is not functional in the human protein or that it
plays a role in other processes. Interestingly, although a
complete knock-down of Dicer is lethal, cells defective for
only the ATPase/helicase domain are viable with only a
defect in miRNA biogenesis [9,37]. Here we show that the
functional importance of the ATPase/helicase domain is
in supporting the interaction with TRBP. These combined
results suggest that the ATPase/helicase domain is not
functional in the human protein, and that the sole func-
tion of this region may be to recruit TRBP through the D1
domain. Interestingly, when searched in BLASTP, D1 has
no homology with any other protein in the databases,
showing its unique properties.
Further demonstration that the C4 domain is solely
responsible for TRBP binding to Dicer is shown by the IP
assays in the presence of complete cell extracts from
tarbp2-/- cells (Fig. 2). In this assay, neither TRBP1ΔC4, nor
TRBP2ΔC4, immunoprecipitated with Dicer. Together
with previous results that showed a direct interaction
between TRBP and Dicer in the absence of RNA or other
proteins, these results confirm that no bridge between
Dicer and TRBP occurs via  dsRNA or another protein.
TRBPsΔC4 and Dicer both have functional dsRBDs that
are able to bind dsRNA. The absence of interaction
between the TRBP mutants and Dicer suggests that they
do not bind the same RNA at the same time.
Dicer and TRBP are cytoplasmic proteins but their colocal-
ization has not been studied. Here, we show that endog-
enous Dicer can be observed in both the nucleus and the
cytoplasm, while TRBP is distributed predominantly in
the cytoplasm (Fig. 1C). Colocalization of the two pro-
teins was found to occur predominantly in the perinuclear
space. Overexpression of TRBPs did not affect their cellu-
lar distribution as immunofluorescence of Myc-tagged
constructs revealed similar staining to that of the endog-
enous protein (Fig. 1C compared to 3A). As neither Myc-
TRBP1ΔC4, nor Myc-TRBP2ΔC4 colocalized with Dicer in
the perinuclear space, we conclude that binding of TRBP
to Dicer is a major determinant of TRBP cellular distribu-
tion and our results suggest that RNAi takes place in the
perinuclear space. In contrast to Myc-TRBP1ΔC4, Myc-
C4 domain in TRBP is required for colocalization with  endogenous Dicer Figure 3
C4 domain in TRBP is required for colocalization 
with endogenous Dicer. HeLa cells were transfected with 
0.5 μg of pCMV-Myc-TRBP1 or pCMV-Myc-TRBP2 (A), 
pCMV-Myc-TRBP1ΔC4 or pCMV-Myc-TRBP2ΔC4 (B), as 
indicated on the left. Cells were fixed and labeled with 
mouse anti-Myc and rabbit anti-Dicer (pAb349) followed by 
anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 546. 
The cells were mounted and assayed for fluorescence by 
laser scanning confocal microscopy on a Zeiss LSM Pascal 5 
microscope. Alexa Fluor 488 and Alexa Fluor 546 fluores-
cences are represented as green and red, respectively, while 
merged colors appear as yellow. Images showing the colocal-
ization of the two proteins detected by the yellow dots or 
absence of colocalization are amplified on the right. C) 
TRBP2 and TRBP2ΔC4 do not colocalize. HeLa cells 
were transfected with 0.5 μg pEGFP-C1-TRBP2 and either 
pCMV-Myc-TRBP2 or pCMV-TRBP2ΔC4. Cells were fixed 
and labeled with anti-Myc followed by anti-mouse Alexa 
Fluor 546. The cells were mounted and assayed as previ-
ously. EGFP signal is shown in green and Alexa Fluor 546 flu-
orescence is represented in red. Images showing 
colocalization of the two proteins detected by yellow dots, 
or absence of colocalization, are amplified of the right.
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TRBP2ΔC4 was partially associated to the cell membrane.
Because TRBP2 has only 21 more aa in its N-terminus
than TRBP1, these aa might be responsible for the mem-
brane association, which is only revealed when its interac-
tion with Dicer is abolished. A closer analysis of the 21 aa
sequence and the protein's posttranslational modifica-
tions will be necessary to elucidate this function.
This slight difference between TRBP1 and TRBP2 also cor-
relates with the rescue of the RNAi function mediated by
shRNAs against EGFP (Figs. 5A and 7A). In these assays,
TRBP1 completely rescued the shRNA activity while
TRBP2 rescued it partially. In contrast, we could not rescue
shRNA activity using the ΔC4 mutants (Figs. 5B and 7C).
This demonstrates that the C4 domain, which mediates
TRBP interaction with Dicer, is also required for RNAi
activity to occur. These results are compatible with a role
of Dicer in the recognition and cleavage of precursor
miRNA and for TRBP in loading small siRNAs into the
RISC [5,13,14]. This study provides new insights into the
interaction between TRBP and Dicer in the RISC. These
results open the way for further studies into differences
between the specific roles of TRBP1 and TRBP2 in the
RNAi pathway.
Conclusion
This is the first study that maps Dicer and TRBP interac-
tion domains precisely to 165 aa and 69 aa regions,
respectively. In Dicer, the motif is located in a unique
region between the ATPase and the helicase domains. In
murine tarbp2-/- cells and in U251MG astrocytoma cells
that do not support and partially support RNAi, respec-
tively, the TRBP1 and TRBP2 isoforms can rescue this
pathway, whereas mutant forms lacking the interacting
domain cannot. TRBP1 and TRBP2 colocalize and immu-
noprecipitate with Dicer whereas the mutants cannot,
suggesting that TRBP and Dicer do not bind to the same
RNA at the same time during the RNAi process.
Methods
Plasmid constructions
pGADGH-Dicer, pGADGH and pGBT9 TRBP and TRBP C
have been described [11]. pGADGH-Cyclin T1 has been
described [38]. TRBP-C fragments (encoding C1: aa 228–
339, C2: aa 340–366, C3: aa 228–297, C4: aa 298–366)
were generated from pcDNA3-TRBP2 [18] by PCR. PCR
products were cut by XmaI and XhoI and subcloned in
frame into the yeast expression vector pGADGH [17]. The
sequences of the primers used are listed below:
TRBP C1 sense: 5'-TCCCCCCGGGGGTGCCTCTGGAT-
GCACGGGATGG-3'
TRBP C1 antisense: 5'-CCAGCTCTCGAGTCACTTGCT-
GCCTGC-3'
TRBP C2 sense: 5'-CCACTGTCCCGGGAATGTCTGCAAC-
CACC-3'
TRBP C2 antisense: 5'-CCTGGTCTCGAGCTAGCCATGAC
ACAC-3'
TRBP C3 antisense: 5'-CCTCAGACTCGAGCTAGAGGAC
ACGGC-3'
TRBP C4 sense: 5'-CTGCCGCCCGGGAATGGAG CTCTC
TGAG-3'
TRBP C1 sense and TRBP C3 antisense primers were used
to clone TRBP C3 cDNA. TRBP C4 sense and TRBP C2
antisense were used to clone TRBP C4 cDNA. pGADGH-
Dicer dsRBD (aa 1850–1922) was generated from pBlue-
script-Dicer-His6 [11] by PCR using 5' TCCCCCCG-
GGGAATGTACCCCGTTCCCCT-3' as sense primer and
5'CACGCGTCGACCTAGGGAACCTGAGGTTGATT-3' as
antisense primer. The PCR fragment cut by XmaI and SalI
was subcloned in frame into pGADGH.
EGFP-C1-TRBP2 [30] and Myc-TRBP1 [25] were previ-
ously described. To construct Myc-TRBP2, the 5' end of
TRBP2 was amplified by PCR using 5'-GCGGAATTCA-
GATGAGTGAAGAGGAG-3' as sense primer and 5'-CTAA-
GATCTTGTGCTTGGCTGCCTTC-3' as antisense primer.
The amplified fragment cut by EcoRI and BglII was
inserted in frame into pCMV-Myc (BD biosciences). The
BstEII-KpnI fragment from pBS-TRBP2 [20] was inserted
into this pCMV-Myc-5'end TRBP2 intermediate. To con-
scruct Myc-TRBP1ΔC4 and Myc-TRBP2ΔC4, a fragment of
TRBP was amplified using the sense primer: 5'-GGAT-
GCCCGGGATGGCAATGAGGTGGAGCCT-3' and anti-
sense primer 5'-GCATGG TACCTCA GACAC GGCAG CA
GGCAGGG-3'. The amplified fragment was cut by XmaI
and KpnI and inserted in frame into pCMV-Myc-TRBP1 or
pCMV-Myc-TRBP2 cut with the same enzymes. The result-
ing proteins have 69 aa deleted in the terminal end of
either TRBP1 or TRBP2. All inserts were verified by
sequencing.
shRNA and miRNA expression cassettes against EGFP
were constructed using a two step PCR method described
previously [39]. In the first PCR step a partial expression
cassette was amplified from pAVU6+27 [40] using the for-
ward primer 5'-GGGCGCGGATCCAAGGTCGGGCAG-
GAAGAGGGCCT-3' and an appropriate reverse primer as
follows:
Non-silencing shRNA:
5'-GTGGCTTCACAGACGTGACACGTTCGGAGAATCG-
CAGTATATGTGCTGCCGAAGCG-3' EGFP shRNA:BMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
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TRBP is required for RNA interference mediated by shRNA or exogenous miRNA against EGFP in murine cells Figure 4
TRBP is required for RNA interference mediated by shRNA or exogenous miRNA against EGFP in murine 
cells. A) Schematic representation of the sh and miRNAs transcribed from pCRII-U6+27 vectors and targeting 
non specific (ns) or EGFP mRNA. The guide strand is shown in red. The seed sequence is highlighted in blue. B, C, D) sh 
and miRNA against EGFP in murine cells are active only when TRBP is present. MEFs (left panels), TEFs hetero-
zygous for TRBP expression (tarbp2+/-; middle panels) or TEFs disrupted for TRBP expression (tarbp2-/-; right panels) were 
transfected with 1 μg of EGFP-C1 and 4 μg of ns or anti-EGFP sh- or mi-RNAs, as indicated. B) Fluorescence of live cells was 
monitored on an inverted microscope and a representative picture is shown. Percentages reflect knock-down of EGFP expres-
sion as calculated by mean luminosity intensity. C) Cells were analyzed by fluorescence automated cell sorting (FACS). 
Reporter expression is calculated as the percentage of EGFP expression in the presence of sh- or miRNA compared to ns nor-
malized to 100%. Values are means of four independent experiments ± SEM. D) Total cell extracts were analyzed by immuno-
blot for EGFP and actin expression. Percent decrease of EGFP signal was calculated by densitometry analysis.BMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
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TRBP1 and TRBP2, but not TRBPsΔC4 rescue the RNAi pathway in tarbp2-/- cells Figure 5
TRBP1 and TRBP2, but not TRBPsΔC4 rescue the RNAi pathway in tarbp2-/- cells. A) TRBP1 and TRBP2 res-
cue the RNAi pathway in tarbp2-/-cells. tarbp2-/- cells were transfected with none or 1 μg of EGFP and 4 μg of non-silenc-
ing (ns) or anti-EGFP (gfp) shRNA as indicated, and 1 μg of pcDNA3 (left panels), pcDNA3-TRBP1 (middle panels) or 
pcDNA3-TRBP2 (right panels). (Top panels) EGFP knock-down was assessed by fluorescence, and average percentages of 
EGFP knockdown were calculated from luminosity intensity values of four fields per condition. Representative photos are 
shown. (Bottom panels) Cell extracts were analyzed by immunoblotting against EGFP and actin. Percent decrease of EGFP sig-
nal was calculated by densitometry analysis. B) TRBP1ΔC4 and TRBP2ΔC4 do not rescue the RNAi pathway in 
tarbp2-/- cells. tarbp2-/- cells were transfected with 1 μg of EGFP and 4 μg of non-silencing (ns) or anti-EGFP (gfp) shRNA as 
indicated, and 1 μg of either pCMV, pCMV-Myc-TRBP1, pCMV-Myc-TRBP1ΔC4, pCMV-Myc-TRBP2 or pCMV-Myc-
TRBP2ΔC4 as indicated. (Top panels) EGFP knock-down was assessed by fluorescence, and average percentages of EGFP 
knockdown were calculated from luminosity intensity values of four fields per condition. Representative photos are shown. 
(Bottom panels) Cell extracts were analyzed by immunoblotting against EGFP and actin. Percent decrease of EGFP signal was 
calculated by densitometry analysis.BMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
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5'-GTGGCTTCACAGCTCCTTGAAGTCGATGCCCTCG-
CAGTCTCTGTGCTGCCGAAGCG-3' With the following
thermal profile: 95°C for 5 min, 30 cycles (95°C for 1
min, 55°C for 1 min, 72°C for 1.5 min), 72°C for 7 min,
using Taq polymerase (Invitrogen). The second PCR was
performed with the matching primer as follows: Non-
silencing miRNA: 5'-CTAGTCTAG AAAAAAAGCAGTTCT
CCGAACGTGTCACGTCCCATCTGTGGCTTCACAGACG
TG-3' EGFP miRNA:
5'-
CTAGTCTAGAAAAAAAGCAGGGGCATCGACTTCAAG-
GAGCCCATCTGTGGCTTCACAGCTCCT-3' shRNA and
miRNA expression vectors were generated by ligation of
the final PCR product into pCR®II-TOPO® (Invitrogen),
and the resulting pCRII-U6+27 vectors confirmed by
sequencing.
Yeast two-hybrid assay
Yeast expression plasmids were introduced into the yeast
reporter strain SFY526. The double transformants were
selected and screened for β-galactosidase activity as
described [25].
Cells and transfections
Human HeLa and astrocytic cells U251MG, murine
embryo fibroblasts (MEF) and primary tail embryonic
fibroblasts tarbp2+/- and tarbp2-/-, described in [26], were
maintained in Dulbecco's modified Eagle's medium
(DMEM; Invitrogen) supplemented with 10% fetal
bovine serum (FBS) (Hyclone), 2 mM L-glutamine and 50
U/ml Penicillin and 50 ug/ml Streptomycin (Invitrogen).
EGFP expression by fluorescence and FACS
Cells were transfected in 6-well plates with 4 μg sh- or mi-
RNA constructs using TransIT Reagent (Mirus) at a 1:3
DNA:TransIT ratio prior to transfection with 1 μg pEGFP-
C1 (Clontech). Cells were observed by fluorescence using
an Axiovert 25 inverted microscope (Zeiss). EGFP expres-
sion was assed by calculating mean luminosity of individ-
ual fields, using Adobe Photoshop CS3 10.0.1 software.
Results are expressed as a percent knock-down, as com-
pared to non-silencing conditions. Cells were analyzed for
EGFP expression by flow cytometry using a FACS Calibur
cytometer (BD) and analyzed using Cellquest software
(BD). Transfected cells were gated by green fluorescence
greater than cells in a mock transfection. Relative fluores-
cence values were calculated as the product of the percent-
ages of EGFP fluorescent cells gated and the mean
fluorescence of cells gated positive.
Immunoblotting
Cell lysates were prepared, separated and transferred for
immunoblotting as previously described [25]. The mem-
brane was blocked for 1 hr in 5% nonfat milk and 0.05%
Tris-buffered saline 20 (TBST) [41]. The membranes were
incubated overnight at 4°C with anti-TRBP 672 [26] at a
1/500 dilution, anti-EGFP and anti-Myc (Santa Cruz)
antibodies at a 1/1000 dilution, or with anti-Dicer349
[11] at a 1/5000 dilution, in 5% milk/TBST. These were
incubated for 1 hr at room temperature with a mono-
clonal anti-actin (Chemicon) at a 1/10,000 dilution. After
5 washes in TBST, membranes were incubated with perox-
idase-conjugated secondary donkey anti-rabbit antibody
(Amersham) for TRBP and Dicer, and sheep anti-mouse
TRBP is required for RNA interference mediated by shRNA  or exogenous miRNA against EGFP in human cells Figure 6
TRBP is required for RNA interference mediated by 
shRNA or exogenous miRNA against EGFP in human 
cells. A) TRBP expression in human cells. Expression 
levels of TRBP was assessed in HeLa, Jurkat and U251MG 
cells using immunoblotting. The TRBP:Actin ratio calculated 
by densitometry is indicated below each lane. B, C, D) sh- 
and miRNA against EGFP are less active in astro-
cytes than in HeLa cells. HeLa (left) or astrocytes 
U251MG (right) cells were transfected with 1 μg of EGFP-C1 
and 4 μg of ns or anti-EGFP sh- or miRNAs as indicated. B) 
Cellular fluorescence of live cells was monitored on an 
inverted microscope and a representative picture is shown. 
Percentages reflect knock-down of EGFP expression as cal-
culated by mean luminosity intensity. C) Cells were analyzed 
by FACS. Reporter expression is calculated as the percent-
age of EGFP expression in the presence of sh or miRNA 
compared to ns normalized to 100%. Values are means of 
four independent experiments ± SEM. D) Total cell extracts 
were analyzed by immunoblot for EGFP and actin expression. 
Percent decrease of EGFP signal was calculated by densitom-
etry analysis.BMC Molecular Biology 2009, 10:38 http://www.biomedcentral.com/1471-2199/10/38
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TRBP1 and TRBP2, but not TRBPsΔC4 rescue the RNAi pathway in U251MG cells Figure 7
TRBP1 and TRBP2, but not TRBPsΔC4 rescue the RNAi pathway in U251MG cells. A) TRBP1 and TRBP2 res-
cue the RNAi pathway in U251MG cells. Human U251MG cells were transfected with none or 1 μg of EGFP and 4 μg of 
either non-silencing (ns) or anti-GFP (gfp) sh- or miRNA, as indicated, and 1 μg of pcDNA3 (left panels), pcDNA3-TRBP1 (mid-
dle panels) or pcDNA3-TRBP2 (right panels). (Top panels) EGFP knock-down was assessed by fluorescence, and average per-
centages of EGFP knockdown were calculated from luminosity intensity values of four fields per condition. Representative 
photos are shown. (Bottom panels) Cell extracts were analyzed by immunoblotting against EGFP and actin. Percent decrease 
of EGFP signal was calculated by densitometry analysis. B) Myc-TRBP1 and TRBP1ΔC4 are equally expressed in 
U251MG cells. U251MG cells were transfected with 1 μg of either pCMV, pCMV-Myc-TRBP1 or pCMV-Myc-TRBP1ΔC4 as 
indicated. Cell extracts were analyzed by immunoblotting against Myc and actin. C) TRBP1ΔC4 and TRBP2ΔC4 do not 
rescue the RNAi pathway in U251MG cells. U251MG cells were transfected with 1 μg of EGFP and 4 μg of non-silencing 
(ns) or anti-EGFP (gfp) shRNA as indicated, and 1 μg of either pCMV, pCMV-Myc-TRBP1, pCMV-Myc-TRBP1ΔC4, pCMV-Myc-
TRBP2 or pCMV-Myc-TRBP2ΔC4 as indicated. (Top panels) EGFP knock-down was assessed by fluorescence, and average per-
centages of EGFP knockdown were calculated from luminosity intensity values of four fields per condition. Representative pho-
tos are shown. (Bottom panels) Cell extracts were analyzed by immunoblotting against EGFP and actin. Percent decrease of 
EGFP signal was calculated by densitometry analysis.
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(Amersham) for EGFP, Myc and Actin at a 1/5000 dilu-
tion. The bands were visualized as previously described
[38]. Bands were quantified by densitometry analysis,
using Adobe Photoshop CS3 10.0.1 software.
Co-immunoprecipitation (co-IP)
48 hrs post-transfection tarbp2-/- cells were washed twice
with PBS and lysed in cold lysis buffer [25] with protease
inhibitors. For each IP, 40 μl of protein G sepharose fast
flow compact beads (Sigma) were washed with TNEN (50
mM Tris-HCl [pH 7.4], 100 mM NaCl, 1 mM EDTA [pH
8], 0.5% NP40 (Sigma) and left rotating at 4°C for 4 hr
with 2 μg anti-Myc (Santa-Cruz) or with 10 μl of mono-
clonal anti-Dicer 73 [11]. 1 mg of cell extract was added to
the beads for overnight incubation at 4°C. The beads were
washed 3 times with 1 ml of cold lysis buffer, 3 times with
1 ml of cold PBS, and resuspended in SDS loading dye.
Bound proteins were eluted by boiling the beads for 10
min and fractionated by 7.5% SDS-PAGE. The immuno-
precipitates were analyzed by immunoblot by using anti-
TRBP 672, anti-Dicer, anti-Myc and anti-actin antibodies.
Immunofluorescence
HeLa cells were cultured on coverslips in 12-well dishes.
Untransfected cells were incubated with mouse anti-Dicer
mAb42 [11] and rabbit anti-TRBP673 [18] antibodies.
The cells were transfected at 50% confluency with Myc-
TRBP1, Myc-TRBP2, Myc-TRBP1ΔC4, Myc-TRBP2ΔC4 or
EGFP-TRBP2 using TransIT (Mirus) reagent. 24 hr post-
transfection, the cells were washed three times with phos-
phate buffered saline (PBS) and fixed at room tempera-
ture for 20 min in PBS containing 4% paraformaldehyde
and 4% sucrose. Cells were then washed three times in
PBS, and permeabilized with 0.1% Triton X-100. The fixed
and permeabilized cells were incubated in PBS containing
3% bovine serum albumin, (Sigma-Aldrich), 3% BSA-
PBS. The cells were then incubated with mouse anti-
Myc9E10 (ATCC), at a 1/500 dilution and rabbit anti-
Dicer 349 [11] at a 1/250 dilution in 3% BSA-PBS at room
temperature for 1 hr. The cells were washed 3 times with
3% BSA-PBS and incubated 1 hr with corresponding sec-
ondary antibodies: anti-rabbit Alexa Fluor 488 and anti-
mouse Alexa Fluor 546 (Invitrogen, Molecular Probes™)
at a 1/1000 dilution in 3% BSA-PBS. Cells were washed 5
times with PBS, rinsed with 95% ethanol, dried and
mounted in Immu-Mount (Thermo-electron corpora-
tion). Cells were analyzed for fluorescence with a 65×
objective on a confocal microscope (Zeiss LSM Pascal 5).
Digital images were converted to TIFF format and com-
piled in Adobe PhotoShop CS3.
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